SK BIOSCIENCE CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57,400 KRW | -0.17% |
|
0.00% | -20.28% |
| Mar. 28 | SK Bioscience Signs Deal with Sanofi for Five Vaccine Types | MT |
| Mar. 07 | SK Bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 17,212,500 | 5,643,627 | 5,528,451 | 4,409,913 | - | - |
| Enterprise Value (EV) 2 | 17,126 | 4,208 | 5,528 | 4,210 | 3,912 | 4,382 |
| P/E ratio | 46.8 x | 46.2 x | - | -114 x | -239 x | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 18.5 x | 12.4 x | 15 x | 17.9 x | 13.8 x | 19.1 x |
| EV / Revenue | 18.4 x | 9.21 x | 15 x | 17.1 x | 12.2 x | 19 x |
| EV / EBITDA | 34.7 x | 29.6 x | - | -488 x | 138 x | - |
| EV / FCF | 34.7 x | -21.3 x | - | -6.9 x | -25.4 x | - |
| FCF Yield | 2.88% | -4.7% | - | -14.5% | -3.93% | - |
| Price to Book | 10.4 x | 3.24 x | - | 2.61 x | 2.65 x | 2.89 x |
| Nbr of stocks (in thousands) | 76,500 | 76,784 | 76,784 | 76,828 | - | - |
| Reference price 3 | 225,000 | 73,500 | 72,000 | 57,400 | 57,400 | 57,400 |
| Announcement Date | 2/7/22 | 2/8/23 | 2/1/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 183.2 | 225.6 | 929 | 456.7 | 369.5 | 245.8 | 320.3 | 231.1 |
| EBITDA 1 | - | - | 493 | 142.3 | - | -8.62 | 28.33 | - |
| EBIT 1 | - | 37.71 | 474.2 | 115 | -11.99 | -68.59 | -45.8 | -118.8 |
| Operating Margin | - | 16.71% | 51.05% | 25.18% | -3.24% | -27.91% | -14.3% | -51.39% |
| Earnings before Tax (EBT) 1 | - | - | 471.1 | 141.7 | 7.327 | -38.36 | -16.38 | - |
| Net income 1 | - | - | 355.1 | 122.5 | 22.32 | -38.66 | -18.58 | - |
| Net margin | - | - | 38.23% | 26.81% | 6.04% | -15.73% | -5.8% | - |
| EPS 2 | 6,933 | - | 4,810 | 1,590 | - | -503.7 | -240.4 | - |
| Free Cash Flow 3 | - | - | 493,686 | -197,951 | - | -610,000 | -153,780 | - |
| FCF margin | - | - | 53,141.65% | -43,341.33% | - | -248,184.23% | -48,013.1% | - |
| FCF Conversion (EBITDA) | - | - | 100,140.23% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 139,011.89% | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/23/21 | 2/7/22 | 2/8/23 | 2/1/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 257.3 | 220.8 | 450.9 | 87.09 | 138.3 | 91.05 | 140.3 | 20.6 | 26.48 | 231.8 | 90.6 | 46.55 | 54.15 | 89 | 67 |
| EBITDA | - | - | - | - | 67.63 | - | 16.56 | -20.92 | - | - | - | - | - | - | - |
| EBIT 1 | - | 100.4 | 253.9 | 23.75 | 61.19 | 21.36 | 8.714 | -29.19 | -35.31 | 60.94 | -8.427 | -18.6 | -18.35 | -1.25 | -6.4 |
| Operating Margin | - | 45.47% | 56.32% | 27.27% | 44.25% | 23.46% | 6.21% | -141.71% | -133.35% | 26.29% | -9.3% | -39.96% | -33.89% | -1.4% | -9.55% |
| Earnings before Tax (EBT) 1 | - | 96.57 | 251.6 | 32.76 | 55.34 | 23.18 | 30.46 | -25.66 | -29.24 | 58.62 | 3.605 | -17.3 | -18.4 | -1 | -4.7 |
| Net income 1 | - | 76.44 | 184 | 27.81 | 46.13 | 20.78 | 27.74 | -14.27 | -15.98 | 48.39 | 4.17 | -13.2 | -14 | -0.7 | -3.6 |
| Net margin | - | 34.61% | 40.8% | 31.93% | 33.36% | 22.82% | 19.77% | -69.27% | -60.34% | 20.87% | 4.6% | -28.36% | -25.85% | -0.79% | -5.37% |
| EPS | 1,342 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/12/21 | 10/29/21 | 2/7/22 | 4/29/22 | 7/29/22 | 10/31/22 | 2/8/23 | 4/27/23 | 7/28/23 | 10/26/23 | 2/1/24 | - | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 86.4 | 1,435 | - | 200 | 498 | 27.7 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 2 | - | - | 493,686 | -197,951 | - | -610,000 | -153,780 | - |
| ROE (net income / shareholders' equity) | - | - | 38.1% | 7.33% | 1.3% | -2.41% | -1.62% | -4.31% |
| ROA (Net income/ Total Assets) | - | - | 26.6% | 5.76% | - | -2.5% | -2.08% | - |
| Assets 1 | - | - | 1,336 | 2,126 | - | 1,546 | 893.5 | - |
| Book Value Per Share 3 | - | - | 21,689 | 22,703 | - | 21,997 | 21,661 | 19,844 |
| Cash Flow per Share 3 | - | - | 7,268 | -1,622 | - | 647.0 | 687.0 | - |
| Capex 1 | - | - | 42.9 | 73 | - | 284 | 171 | - |
| Capex / Sales | - | - | 4.62% | 15.98% | - | 115.48% | 53.44% | - |
| Announcement Date | 3/30/20 | 3/23/21 | 2/7/22 | 2/8/23 | 2/1/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
57,400
KRW
Average target price
58,000
KRW
Spread / Average Target
+1.05%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.28% | 3.2B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- A302440 Stock
- Financials SK bioscience Co.,Ltd.
